Search Results 971-980 of 18059 for monoclonal antibody

1. Headache Management Service - Mayo Clinic Healthcare

   Our chronic migraine treatment uses VYEPTI infusions, delivered intravenously. VYEPTI is a monoclonal antibody that targets calcitonin gene-related peptide ( ...

2. Publications - Kayla R. Mirie, M.D. - Mayo Clinic

   Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients. Transpl Infect Dis. 2022 Feb; 24 (1):e13759 Epub 2021 Dec 07. View PubMed ...

3. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab Monotherapy In Participants With Select B-Cell Malignancies (MorningSun) - Mayo Clinic

   monoclonal antibodies (MAbs). ... Exclusion Criteria Specific to Cohorts D and E. - Prior use of any monoclonal antibody (e.g., anti-CD20), radioimmunoconjugate, ...

4. A Study of Using Lorvotuzumab Mertansine in Treating Younger Patients with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma - Mayo Clinic

   Antibody-drug conjugates, such as lorvotuzumab mertansine, are created by ... monoclonal antibody; ≥ 2 weeks must have elapsed since local palliative ...

5. Mayo Clinic Q&A podcast: Less pain and faster recovery with minimally invasive heart surgery

   Monoclonal antibodies: Update on this COVID-19 experimental therapy. Related Articles. Brain-body connection: Expert shares tips to reduce risk of cognitive ...

6. A Study to Evaluate Alloantibody Titer in Highly Sensitized Kidney Transplant Candidates - Mayo Clinic

   The purpose of this study is to evaluate the utility of using anti-HLA antibody titer to measure the effectiveness of antibody lowering therapy (i.e. ...

7. Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence.

   ... monoclonal gammopathy of undetermined significance and implications for recategorizing disease entities, which will be published in the October 2010 issue ...

8. Experimental Treatments Clinical Trials - Mayo Clinic Research

   ... monoclonal anti-CD20 antibody, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma (NHL). A Phase 1 AAV Gene Therapy Trial Evaluating ...

9. Dose-Escalation Study Of Cevostamab (BFCR4350A) In Participants With Relapsed Or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

   History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins). Patients with known ...

10. A Study Of TNB-383B In Subjects With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

    ... monoclonal antibody (i.e., daratumumab). Subject has Measurable Disease, defined as at least 1 of the following: Serum M-protein ≥ 0.5 g/dL (≥ 5 g/L);.